Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11939
Title: The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
Authors: Carter, Hannah E;Zannino, Diana;John Simes, R;Schofield, Deborah J;Howard, Kirsten;Zalcberg, John R;Price, Timothy J;Tebbutt, Niall C
Affiliation: NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 2050, Australia. Electronic address: hannah.carter@ctc.usyd.edu.au.
NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 2050, Australia.
School of Public Health, The University of Sydney, Edward Ford Building, NSW 2006, Australia.
Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, VIC 8006, Australia; Department of Oncology, University of Melbourne, Australia.
The Queen Elizabeth Hospital, 28 Woodville Rd, Woodville, SA 5011, Australia; The University of Adelaide, Australia.
Austin Health, PO Box 5555, Heidelberg, VIC 3084, Australia.
Issue Date: 8-Nov-2013
Citation: European Journal of Cancer (oxford, England : 1990) 2013; 50(3): 535-43
Abstract: Based on the clinical data, bevacizumab has been approved in Australia and globally for the treatment of advanced colorectal cancer. However, limited evidence exists for its cost-effectiveness. The purpose of this study was to evaluate the cost effectiveness of adding bevacizumab to capecitabine monotherapy in patients with metastatic colorectal cancer, using data from the prospective economic evaluation conducted alongside the MAX trial.Individual patient level data on resource use and progression free survival were prospectively collected in the phase III MAX trial. Resource use data were collected for the period between randomisation and disease progression, and unit costs were assigned from the perspective of the Australian health care funder. Effectiveness was measured in quality adjusted progression free survival years, with utility scores obtained from both the community valued EQ-5D questionnaire and the patient valued UBQ-C questionnaire. Progression free survival was used as a secondary effectiveness measure.The addition of bevacizumab to capecitabine monotherapy cost approximately $192,156 (95% confidence interval [CI], $135,619 to $326,894) per quality adjusted progression free survival year gained when using publicly listed pharmaceutical prices and utility values from the EQ-5D questionnaire. This decreased to $149,455 (95% CI, $100,356 to $245,910) when values from the UBQ-C questionnaire were applied. The incremental cost per progression free survival year was $145,059 (95% CI, $106,703 to $233,225).Bevacizumab was not found to be cost effective at its listed price, based on results from the MAX trial.
Internal ID Number: 24215848
URI: http://ahro.austin.org.au/austinjspui/handle/1/11939
DOI: 10.1016/j.ejca.2013.09.028
URL: http://www.ncbi.nlm.nih.gov/pubmed/24215848
Type: Journal Article
Subjects: Bevacizumab
Cancer
Colorectal
Cost
Effectiveness
MAX
Antibodies, Monoclonal, Humanized.administration & dosage
Antimetabolites, Antineoplastic.administration & dosage
Antineoplastic Combined Chemotherapy Protocols.adverse effects.economics.therapeutic use
Australia
Colorectal Neoplasms.drug therapy.economics.pathology
Deoxycytidine.administration & dosage.analogs & derivatives
Disease-Free Survival
Female
Fluorouracil.administration & dosage.analogs & derivatives
Humans
Male
Mitomycin.economics
Quality of Life
Treatment Outcome
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.